Medicine pack check sheet

Source-linked reading points

• This public label lists 250 mg film-coated oral tablets; round, brown, biconvex tablets debossed “IRESSA 250” are identity clues in this U.S. label. Check mg, appearance, pack count and brand together. A difference in any one of them does not establish the same product, authenticity or packaging in another market.
• The label gives a specific water-dispersion procedure for this exact tablet when solid dosage forms cannot be swallowed. It is not general permission to split, crush, store, or mix tablets with food or another liquid; handling of an actual pack needs confirmation against the current target-market label by the oncology team or pharmacist.
• The label flags enzyme inducers/inhibitors that affect gefitinib exposure, medicines affecting gastric acidity and warfarin-related bleeding monitoring. Stomach medicines, anti-infectives, herbs, anticoagulants and every prescription/OTC product should be reviewed with the actual packages by the oncology team or pharmacist; a webpage cannot decide individual co-use, spacing or adjustment.
• With new or worsening breathing difficulty, cough or fever, persistent or severe diarrhoea, jaundice-like changes, severe rash/blistering, eye pain or vision change, contact the treatment team promptly or use local urgent medical support. Do not self-pause, restart or change to another EGFR medicine from a webpage, one test result or another patient's experience.